Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA And Sponsors Resolve Disclosure Issues On Complex Trial Design Pilot Projects

Executive Summary

Agency officials can now discuss the ideas that have been accepted, though not in great detail.

You may also be interested in...



PDUFA VII: Human Factors Review, Finance Flexibility, REMS, And Manufacturing Get Attention

User fee reauthorization negotiators from US FDA and industry divide into subgroups to tackle specific issues before moving to the broader agreement.

How US FDA And Industry Are Looking To Navigate New Supply Chain Data Reporting Requirements

FDA Commissioner Hahn says industry needs to work with the agency to establish a link to more detailed supply chain information.

PDUFA VII: Will Gene Therapy's Rise Influence Talks?

The Center for Biologics Evaluation and Research may need more fee revenue to add employees to handle the increasing cell and gene therapy workload.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS141805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel